Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

This study has been completed.
Information provided by (Responsible Party):
PLx Pharma Identifier:
First received: January 13, 2012
Last updated: February 11, 2016
Last verified: February 2016
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as these other products, when administered to patients with diabetes.

Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: PL2200 Aspirin Capsules
Drug: Immediate-Release Aspirin Tablets
Drug: Enteric-coated aspirin caplets
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Actively Controlled, Crossover Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Patients With Type II Diabetes

Resource links provided by NLM:

Further study details as provided by PLx Pharma:

Primary Outcome Measures:
  • Time to 99% Inhibition of Serum Thromboxane (TxB2) [ Time Frame: 4 days ]
    Aspirin's antiplatelet activity is measured by the capacity of platelets to generate serum thromboxane (a surrogate marker for inhibition of COX-1 by aspirin). Inhibition of serum thromboxane is a key marker of antiplatelet efficacy.

Enrollment: 40
Study Start Date: January 2012
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PL2200 Aspirin Capsules
Investigational drug arm; crossover design
Drug: PL2200 Aspirin Capsules
325 mg aspirin; once per day for 3 days
Active Comparator: Immediate-Release Aspirin Tablets
Active comparator; crossover design
Drug: Immediate-Release Aspirin Tablets
325 mg aspirin; once per day for 3 days
Active Comparator: Enteric-coated aspirin caplets
Active comparator; crossover design
Drug: Enteric-coated aspirin caplets
325 mg aspirin; once per day for 3 days


Ages Eligible for Study:   21 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults 21-79
  • Body mass index (BMI) of 30-40 kg/m2
  • Non-insulin-dependent type-2 diabetics (as confirmed by hemoglobin A1c (HbA1c) of > 6.4% and/or fasting plasma glucose of >125 mg/dL or current anti-diabetic medication)
  • AA-induced platelet aggregation response of >60% within 3 hours prior to initial dose of study drug administration

Exclusion Criteria:

  • Contraindications to aspirin
  • Previous history of vascular disease
  • Patient requires insulin
  • Use of non-steroidal anti-inflammatory drugs, anti-secretory agents, antacids, and salicylate-containing nutritional supplements within 2 weeks of randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01515657

United States, Ohio
MedPace Clinical Pharmacology
Cincinnati, Ohio, United States, 45212
Sponsors and Collaborators
PLx Pharma
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: PLx Pharma Identifier: NCT01515657     History of Changes
Other Study ID Numbers: PL-ASA-004
Study First Received: January 13, 2012
Results First Received: June 22, 2015
Last Updated: February 11, 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics processed this record on May 25, 2017